Literature DB >> 23163622

Ancillary testing, diagnostic/classification criteria and severity grading in Behçet disease.

Annabelle A Okada1, Miles Stanford, Khalid Tabbara.   

Abstract

Since there is no pathognomonic clinical sign or laboratory test to distinguish Behçet disease from other uveitic entities, the diagnosis must be made based on characteristic ocular and systemic findings in the absence of evidence of other disease that can explain the findings. Ancillary tests, including ocular and brain imaging studies, are used to assess the severity of intraocular inflammation and systemic manifestations of Behçet disease, to identify latent infections and other medical conditions that might worsen with systemic treatment, and to monitor for adverse effects of drugs used. There are two diagnostic or classification criteria in general use by the uveitis community, one from Japan and one from an international group; both rely on a minimum number and/or combination of clinical findings to identify Behçet disease. Finally, several grading schemes have been proposed to assess severity of ocular disease and response to treatment.

Entities:  

Mesh:

Year:  2012        PMID: 23163622     DOI: 10.3109/09273948.2012.723111

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  3 in total

1.  Type I Interferon Therapy Limits CNS Autoimmunity by Inhibiting CXCR3-Mediated Trafficking of Pathogenic Effector T Cells.

Authors:  Weiwei Wang; Wai Po Chong; Chunmei Li; Zilin Chen; Sihan Wu; Hongyan Zhou; Ying Wan; Wanjun Chen; Igal Gery; Yizhi Liu; Rachel R Caspi; Jun Chen
Journal:  Cell Rep       Date:  2019-07-09       Impact factor: 9.423

2.  Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up.

Authors:  F Groen; W Ramdas; J de Hoog; J R Vingerling; A Rothova
Journal:  Eye (Lond)       Date:  2016-01-08       Impact factor: 3.775

3.  Birmingham Behçet's service: classification of disease and application of the 2014 International Criteria for Behçet's Disease (ICBD) to a UK cohort.

Authors:  Tim Blake; Luke Pickup; David Carruthers; Erika Marie Damato; Alastair Denniston; John Hamburger; Claire Maxton; Debbie Mitton; Philip I Murray; Peter Nightingale; Ana Poveda-Gallego; Andrea Richards; Andrew Whallett; Deva Situnayake
Journal:  BMC Musculoskelet Disord       Date:  2017-03-11       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.